RUN vs ZYME · P/E 6.0, rev $2.04B vs rev $76.3M
Sunrun Inc (RUN) versus Zymeworks Inc. Common Stock (ZYME) — a side-by-side from cached financials, not a winner call.
Sunrun Inc (RUN) is a solar company listed on NASDAQ.
Zymeworks Inc. Common Stock (ZYME) is a biotechnology company listed on NASDAQ.
Latest reported RUN revenue for 2024-12-31 was $2.04B. Net income was -$4.36B. Revenue was down 9.8% from 2023-12-31 to 2024-12-31. RUN currently screens at market cap $3.05B and trailing P/E 6.0.
Latest reported ZYME revenue for 2024-12-31 was $76.3M. Net income was -$122.7M. Revenue was up 0.4% from 2023-12-31 to 2024-12-31. ZYME currently screens at market cap $1.68B.
RUN currently screens at market cap $3.05B and trailing P/E 6.0. ZYME currently screens at market cap $1.68B.
Not investment advice. Open the RUN and ZYME stock pages for the full models.
Not investment advice.